日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast Cancer.

LMP7 特异性抑制剂 M3258 调节三阴性乳腺癌和炎性乳腺癌的肿瘤微环境

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17111887
Xie Xuemei, Lee Jangsoon, Manyam Ganiraju C, Pearson Troy, Walter-Bausch Gina, Friese-Hamim Manja, Zhao Sheng, Jabs Julia, Manginelli Angela A, Piske Nadine, Mrowiec Thomas, Wolf Corinna M, Kuntal Bharat S, Tripathy Debu, Wang Jing, Sanderson Michael P, Ueno Naoto T
肿瘤
乳腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Tepotinib 的临床前药理学研究——一种对携带 MET 改变的肿瘤具有活性的高选择性 MET 抑制剂

期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-22-0537
Albers, Joachim; Friese-Hamim, Manja; Clark, Anderson; Schadt, Oliver; Walter-Bausch, Gina; Stroh, Christopher; Johne, Andreas; Karachaliou, Niki; Blaukat, Andree
肿瘤
MET
肿瘤免疫
发表日期：2023
文献求助 收藏

Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

利用口服MET抑制剂tepotinib的临床前和临床数据进行转化药代动力学-药效学建模，以确定推荐的II期剂量。

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12602
Xiong, Wenyuan; Friese-Hamim, Manja; Johne, Andreas; Stroh, Christopher; Klevesath, Manfred; Falchook, Gerald S; Hong, David S; Girard, Pascal; El Bawab, Samer
MET
发表日期：2021
文献求助 收藏